SCHEMBL367447

SCHEMBL367447

[CH2]N1C=COC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9439880 0.63
SCHEMBL1549773 0.62
SCHEMBL7973609 0.62
SCHEMBL1549774 0.62
SCHEMBL2255302 0.62
SCHEMBL11513404 0.61
SCHEMBL940708 0.59
SCHEMBL23198641 0.57
SCHEMBL8675904 0.56
SCHEMBL7104332 0.47

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104844507-A Application of quinolinone compounds to inhibit growth of alga and algicide for inhibiting growth of alga UNIV HUAZHONG NORMAL 2015-08-19 CN claimed
CN-103508950-A 4-hydroxy-2-quinolinone compounds containing imine structure, and preparation and application thereof UNIV NANKAI 2014-01-15 CN claimed
US-20040254344-A1 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues XENOPORT 2004-12-16 US claimed
EP-1412324-A4 AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES XENOPORT INC (US) 2004-09-29 EP claimed
EP-1412324-A2 AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES Xenoport, Inc. (US) 2004-04-28 EP claimed
US-20030181390-A1 Amino acid conjugates providing for sustained systemic concentrations of GABA analogues XENOPORT, INC. 2003-09-25 US claimed
WO-2002100344-A2 AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES XENOPORT, INC. (US) 2002-12-19 WO claimed
WO-2024105016-A1 NOVEL BICYCLIC[1,2,4]TRIAZOLONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS ADDEX PHARMA S.A. (CH) 2024-05-23 WO disclosed
WO-2024105018-A1 NOVEL PYRROLO[1,2-d][1,2,4]TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS ADDEX PHARMA S.A. (CH) 2024-05-23 WO disclosed
WO-2024105021-A1 NOVEL PYRROLO[1,2-d][1,2,4]TRIAZIN-1-ONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS ADDEX PHARMA S.A. (CH) 2024-05-23 WO disclosed
EP-4337643-A1 SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR Addex Pharma S.A (CH) 2024-03-20 EP disclosed
EP-4337664-A1 FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR Addex Pharma S.A (CH) 2024-03-20 EP disclosed
CN-111527090-B Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors 拜耳公司 2023-05-26 CN disclosed
EP-1412324-A4 AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES XENOPORT INC (US) 2004-09-29 EP disclosed
EP-1412324-A2 AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES Xenoport, Inc. (US) 2004-04-28 EP disclosed
CN-1473163-A Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors 2004-02-04 CN disclosed
US-20030181390-A1 Amino acid conjugates providing for sustained systemic concentrations of GABA analogues XENOPORT, INC. 2003-09-25 US disclosed
WO-2002100344-A2 AMINO ACID CONJUGATES PROVIDING FOR SUSTAINED SYSTEMIC CONCENTRATIONS OF GABA ANALOGUES XENOPORT, INC. (US) 2002-12-19 WO disclosed
CN-1081676-A The indoles and the indazole derivatives that are used for the treatment and the prevention of cerebral disorders, their preparation and application SANKYO CO (JP) 1994-02-09 CN disclosed
EP-0562832-A1 Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use SANKYO COMPANY LIMITED (JP) 1993-09-29 EP disclosed